• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

BLU2864

CAS No. 2810747-89-6

BLU2864 ( —— )

产品货号. M35362 CAS No. 2810747-89-6

BLU2864 是一种具有口服活性的、高选择性的、ATP 竞争性的 PRKACA 抑制剂 (IC50=0.3 nM)。BLU2864 具有抗肿瘤活性,可用于癌症和多囊肾的研究。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
2MG ¥1072 有现货
5MG ¥1680 有现货
10MG ¥2729 有现货
25MG ¥4168 有现货
50MG ¥5771 有现货
100MG ¥7650 有现货
200MG ¥10328 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    BLU2864
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    BLU2864 是一种具有口服活性的、高选择性的、ATP 竞争性的 PRKACA 抑制剂 (IC50=0.3 nM)。BLU2864 具有抗肿瘤活性,可用于癌症和多囊肾的研究。
  • 产品描述
    BLU2864 is an orally active, highly selective, ATP-competitive PRKACA inhibitor (IC50=0.3 nM). BLU2864 shows anti-tumor activity. BLU2864 can be used in cancer and polycystic kidney disease research.
  • 体外实验
    BLU2864 (40 nM and 200 nM; 5 d) inhibits forskolin (HY-15371)-induced in vitro cystogenesis.Cell Viability Assay Cell Line:mIMCD3 cells Concentration:40 nM and 200 nM Incubation Time:5 days Result:Inhibited forskolin induced in vitro cystogenesis of mIMCD3 cells cultured in Matrigel by 72% and 100% at 40 and 200 nM concentrations, respectively, relative to control.
  • 体内实验
    BLU2864 (oral gavage; 45 mg/kg; once daily; 5 d) inhibits renal PKA activity in Pkd1RC/RC mice.BLU2864 (oral gavage; 30 mg/kg; once daily; 5 d) inhibits PKA activity and ameliorates PKD in Pkd1RC/RC mice. BLU2864 (oral gavage; 30 mg/kg and 75 mg/kg; once daily; 34 d) reduces FLC tumor growth in vivo.Animal Model:Pkd1RC/RC mice Dosage:45 mg/kg Administration:Oral gavage; 45 mg/kg; once daily; 5 days Result: Suppressed kidney basal and total PKA activities by 74% and 87% at 3 hours and by 46% and 56% at 15 hours, respectively, in the BLU2864-treated mice compared with controls.Animal Model:Pkd1RC/RC mice Dosage:30 mg/kg Administration:Oral gavage; 30 mg/kg; once daily; 5 days Result:Showed higher urine outputs at 15 weeks in the BLU2864-treated mice than in the controls. Showed lower kidney weights, kidney volumes as percent of body weights, and cyst indices. Showed renal basal and total PKA activities by 69% and 84% lower in the BLU2864-treated mice compared with controls.Animal Model:Mice harboring FLC PDX tumors Dosage:30 mg/kg and 75 mg/kg Administration:Oral gavage; 30 mg/kg and 75 mg/kg; once daily; 34 days Result:Inhibited tumor growth by 48.5% (P=0.003) and by 45.3% (P=0.0005), respectively, at day 34.
  • 同义词
    ——
  • 通路
    Others
  • 靶点
    Other Targets
  • 受体
    Others
  • 研究领域
    ——
  • 适应症
    ——

化学信息

  • CAS Number
    2810747-89-6
  • 分子量
    452.43
  • 分子式
    C24H19F3N4O2
  • 纯度
    >98% (HPLC)
  • 溶解度
    In Vitro:?DMSO 中的溶解度 : 100 mg/mL (221.03 mM; 超声助溶 )
  • SMILES
    N(C(=O)C=1C=CC(=NC1)C2=C3C(NC=C3C)=NC=C2)[C@@H]4C=5C(=CC(C(F)F)=CC5F)C[C@@H]4O
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Xiaofang Wang, et al. Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease. J Am Soc Nephrol. 2022 Jun;33(6):1087-1104.?
产品手册
关联产品
  • Nelivaptan

    Nelivaptan 是一种非肽加压素受体拮抗剂,对 V1B 亚型具有选择性。

  • GPDA

    GPDA 是酶测定中 X-脯氨酰二肽基氨基肽酶的底物。

  • (-)-Syringaresinol

    (-)-丁香脂素源自蒙大拿番荔枝的茎。 (-)-Syringaresinol 通过 G1 期阻滞和诱导细胞凋亡来抑制人早幼粒细胞 HL-60 细胞的增殖,并具有抗癌活性。